Lancet

Article	Citations
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	7369
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis	4775
Endothelial cell infection and endotheliitis in COVID-19	4736
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission	4537
Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	3796
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK	3597
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study	3098
Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis	2656
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial	2548
Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic	2118
COVID-19 and Italy: what next?	2060
Gastric cancer	1991
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial	1913
Hyperinflammatory shock in children during COVID-19 pandemic	1787
An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study	1744
Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study	1568
Alzheimer's disease	1523
Pancreatic cancer	1332
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational	1311
Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study	1287
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia	1268
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study	1254
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	1230
Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants	1214
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 tr	1194

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study	1192
Parkinson's disease	1188
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial	1116
Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study	1109
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial	1083
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study	1059
Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019	1040
Non-alcoholic fatty liver disease	1025
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic	1010
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial	999
The 2020 report of The Lancet Countdown on health and climate change: responding to converging crises	948
Sex and gender: modifiers of health, disease, and medicine	937
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial	933
COVID-19 exacerbating inequalities in the US	932
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-	926
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study	915
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials	901
Lung cancer	895
Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21	878
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study	858
Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global	855
SARS-CoV-2 and viral sepsis: observations and hypotheses	847
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness	844
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment	837
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study	828
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study	812
Atopic dermatitis	809
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials	799
Psoriasis	788
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia	772
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study	740
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression	734
Chronic pain: an update on burden, best practices, and new advances	728
Breast cancer	705
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence	692
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label	680
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study	678
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial	668
Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study	663
1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study	661
The 2021 report of the Lancet Countdown on health and climate change: code red for a healthy future	658
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey	648
Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry	628
First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment	626
Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series	622
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study	621
Ten scientific reasons in support of airborne transmission of SARS-CoV-2	615
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial	613
Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study	612
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (	603

Offline: COVID-19 is not a pandemic	593
Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burd	586
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial	566
COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study	561
Parenting in a time of COVID-19	556
Virtual health care in the era of COVID-19	551
Hepatocellular carcinoma	541
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial	536
Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the Z	534
Lessons learnt from easing COVID-19 restrictions: an analysis of countries and regions in Asia Pacific and Europe	534
The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030	527
Stroke	526
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)	525
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial	519
Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study	517
Liver cirrhosis	516
Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial	508
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled,	501
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial	499
Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss	499
Oxford–AstraZeneca COVID-19 vaccine efficacy	496
COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England	495
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial	488
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	488
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates	484
Fangcang shelter hospitals: a novel concept for responding to public health emergencies	479
Chronic kidney disease	477
Hot weather and heat extremes: health risks	474
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial	471
Immune checkpoint inhibitors in melanoma	465
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination	460
Male infertility	456
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study	455
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis	451
Beware of the second wave of COVID-19	448
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed	438
Nociplastic pain: towards an understanding of prevalent pain conditions	432
SARS-CoV-2 variants and ending the COVID-19 pandemic	431
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial	430
Acute pancreatitis	427
Gout	425
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial	424
Acute respiratory distress syndrome	419
Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination	418
Biliary tract cancer	415
Bipolar disorders	414
Low back pain	412
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo	412
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial	410
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial	408
The 2022 report of the Lancet Countdown on health and climate change: health at the mercy of fossil fuels	402
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial	402
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis	399
Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study	388
Endometriosis is a chronic systemic disease: clinical challenges and novel innovations	387
Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study	386
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial	385
Iron deficiency	385
First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA	384
Dementia care during COVID-19	382
Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019	375
RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis	374
Quality of primary health care in China: challenges and recommendations	374
Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study	373
Retinal findings in patients with COVID-19	373
Pre-eclampsia	364
Kawasaki-like disease: emerging complication during the COVID-19 pandemic	363
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised cont	361
Osteoarthritis in 2020 and beyond: a Lancet Commission	354
Hearing loss prevalence and years lived with disability, 1990–2019: findings from the Global Burden of Disease Study 2019	352
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals	350
Irritable bowel syndrome	350
Multiple myeloma	348
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial	346
India under COVID-19 lockdown	345
Ethnicity and COVID-19: an urgent public health research priority	342
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial	339
Obesity could shift severe COVID-19 disease to younger ages	335
Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis	334
Racism and discrimination in COVID-19 responses	334

COVID-19 in Brazil: “So what?”	332
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1	331
Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial	331
Global, regional, and national prevalence estimates of physical or sexual, or both, intimate partner violence against women in 2018	330
Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study	329
Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2	329
Endometrial cancer	324
Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenS	323
COVID-19: the case for health-care worker screening to prevent hospital transmission	323
Acute lymphoblastic leukaemia	318
Cystic fibrosis	316
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives	311
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study	311
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials	310
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised	307
Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial	304
Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study	304
Migraine: epidemiology and systems of care	304
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial	304
The Lancet Commission on the future of care and clinical research in autism	303
Five insights from the Global Burden of Disease Study 2019	303
WHO International Standard for anti-SARS-CoV-2 immunoglobulin	300
The Lancet Commission on lessons for the future from the COVID-19 pandemic	299
Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study	297
The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study	296
Developing antibody tests for SARS-CoV-2	295
Time for united action on depression: a Lancet–World Psychiatric Association Commission	294
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial	292
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum	290
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label,	283
Head and neck cancer	282
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021	282
Artificial intelligence and the future of global health	281
Revisiting maternal and child undernutrition in low-income and middle-income countries: variable progress towards an unfinished agenda	279
Schizophrenia	277
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-grou	274
Considering BCG vaccination to reduce the impact of COVID-19	273
Impacts of COVID-19 on childhood malnutrition and nutrition-related mortality	272
Refugee and migrant health in the COVID-19 response	271
Detection of SARS-CoV-2 in human breastmilk	271
The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study	271
COVID-19: PCR screening of asymptomatic health-care workers at London hospital	270
Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial	269
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial	268
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cel	267
The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019	267
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial	266
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial	264
Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials	264
Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine	264
Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose	261
Guillain-Barré syndrome	259
Mass gathering events and reducing further global spread of COVID-19: a political and public health dilemma	256
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial	256
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controll	255
Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study	255
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 stu	254
Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry	254
Considerations in boosting COVID-19 vaccine immune responses	254
Fragmented health systems in COVID-19: rectifying the misalignment between global health security and universal health coverage	254
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study	253
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials	251
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality	251
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients	249
Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004–18	248
Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study	247
Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial	246
Venous thromboembolism	246
Chronic pancreatitis	245
Challenges for the female academic during the COVID-19 pandemic	243
Redefining vulnerability in the era of COVID-19	242
Sputnik V COVID-19 vaccine candidate appears safe and effective	241
Prostate cancer	241
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial	239
SARS-CoV-2 renal tropism associates with acute kidney injury	239
Association of metabolic–bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 part	239
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical tr	236
First experience of COVID-19 screening of health-care workers in England	236
From race-based to race-conscious medicine: how anti-racist uprisings call us to act	236
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial	236
Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study	235
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, ac	234
Chronic obstructive pulmonary disease	232
Wearing face masks in the community during the COVID-19 pandemic: altruism and solidarity	230
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial	228
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial	227
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data	226
Functional dyspepsia	226
Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study	226
Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic	225
Early evidence of pronounced brain involvement in fatal COVID-19 outcomes	224
Diagnostics for COVID-19: moving from pandemic response to control	222
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications	220
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis	220
Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study	219